▲ +91.73% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Lexicon Pharmaceuticals in the last 3 months. The average price target is $2.55, with a high forecast of $3.00 and a low forecast of $2.10. The average price target represents a 91.73% upside from the last price of $1.33.
The current consensus among 6 contributing investment analysts is to hold stock in Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.